Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 917562-33-5 Chemical Structure| 917562-33-5

Structure of JT010
CAS No.: 917562-33-5

Chemical Structure| 917562-33-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JT010 is an agonist of TRPA1 with EC50 of 0.65 nM.

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JT010

CAS No. :917562-33-5
Formula : C16H19ClN2O3S
M.W : 354.85
SMILES Code : COC1=CC=C(C=C1)C2=CSC(N(CCCOC)C(CCl)=O)=N2
English Name :2-Chloro-N-(4-(4-methoxyphenyl)thiazol-2-yl)-N-(3-methoxypropyl)acetamide
MDL No. :MFCD08899142

Safety of JT010

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse DRG cells 10 nM To validate endogenous mouse TRPA1 activation by JT010, showing no response despite AITC sensitivity Int J Mol Sci. 2022 Nov 18;23(22):14297
Human FLSs 10 nM 24 hours To validate endogenous human TRPA1 activation by JT010, showing significant responses in inflamed FLSs Int J Mol Sci. 2022 Nov 18;23(22):14297
HEK-mTRPA1 cells 10 nM To validate JT010 activation of mouse TRPA1, showing minimal response compared to 100 μM AITC Int J Mol Sci. 2022 Nov 18;23(22):14297
HEK-hTRPA1 cells 0.3–100 nM To validate JT010 activation of human TRPA1, showing effective Ca2+ responses with EC50 ~10 nM Int J Mol Sci. 2022 Nov 18;23(22):14297
oligodendrocytes 10 nM 24 hours TRPA1 activation causes demyelination but no significant change in oligodendrocyte number Glia. 2023 Jun;71(6):1402-1413
oligodendrocytes 10 nM 10 days TRPA1 activation causes demyelination and loss of oligodendrocyte lineage cells Glia. 2023 Jun;71(6):1402-1413
CD14+ monocytes 40 µM 10 minutes JT010 at 40 µM significantly elevated intracellular Ca2+ levels but had no significant effect on CD14+ monocyte activation. Biomolecules. 2024 May 28;14(6):632
CD4+ T lymphocytes 40 µM 10 minutes JT010 at 40 µM significantly inhibited T-cell receptor (TcR)-induced Ca2+ signals, indicating an inhibitory effect on T cell activation. Biomolecules. 2024 May 28;14(6):632
UCN1-immunoreactive neurons 5 μM To prove the functional activity of TRPA1 in UCN1 neurons, JT010 significantly increased the spontaneous firing frequency of UCN1-immunoreactive neurons Front Cell Dev Biol. 2023 Jan 10;10:1046559

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.82mL

0.56mL

0.28mL

14.09mL

2.82mL

1.41mL

28.18mL

5.64mL

2.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories